Relmada Therapeutics annual shares outstanding
2014
2015
2016
2017
2018
2019
2019
2020
2021
2022
2023
2024
2025
Relmada Therapeutics Shares Outstanding History (RLMD)
Relmada Therapeutics reported 73.3M shares outstanding at the end of fiscal 2025.
View full Relmada Therapeutics company overviewRelmada Therapeutics annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 73.3M | 43.2M | +143.03% |
| 2024 | 2024-12-31 | 30.2M | 74,999 | +0.25% |
| 2023 | 2023-12-31 | 30.1M | 0 | 0.00% |
| 2022 | 2022-12-31 | 30.1M | 2.4M | +8.50% |
| 2021 | 2021-12-31 | 27.7M | 11.4M | +69.84% |
| 2020 | 2020-12-31 | 16.3M | 1.9M | +12.98% |
| 2019 · Dec 31 | 2019-12-31 | 14.5M | 4.7M | +48.36% |
| 2019 · Jun 30 | 2019-06-30 | 9.7M | 6.6M | +210.59% |
| 2018 | 2018-06-30 | 3.1M | −9.4M | −74.96% |
| 2017 | 2017-06-30 | 12.5M | 493,337 | +4.10% |
| 2016 | 2016-06-30 | 12.0M | 1.3M | +11.66% |
| 2015 | 2015-06-30 | 10.8M | 2.7M | +33.75% |
| 2014 | 2014-06-30 | 8.1M | — | — |
Relmada Therapeutics quarterly shares outstanding
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 106.7M | 73.5M | +221.38% |
| Q1 2026 | 2026-03-31 | 104.9M | 71.7M | +216.01% |
| Q4 2025 | 2025-12-31 | 73.3M | 43.2M | +143.03% |
| Q3 2025 | 2025-09-30 | 33.2M | 3.0M | +10.00% |
| Q2 2025 | 2025-06-30 | 33.2M | 3.0M | +10.00% |
| Q1 2025 | 2025-03-31 | 33.2M | 3.0M | +10.00% |
| Q4 2024 | 2024-12-31 | 30.2M | 74,999 | +0.25% |
| Q3 2024 | 2024-09-30 | 30.2M | 74,999 | +0.25% |
| Q2 2024 | 2024-06-30 | 30.2M | 74,999 | +0.25% |
| Q1 2024 | 2024-03-31 | 30.2M | 74,999 | +0.25% |
| Q4 2023 | 2023-12-31 | 30.1M | 0 | 0.00% |
| Q3 2023 | 2023-09-30 | 30.1M | 1.5M | +5.09% |
| Q2 2023 | 2023-06-30 | 30.1M | 28.6M | +1972.93% |
| Q1 2023 | 2023-03-31 | 30.1M | 74,609 | +0.25% |
| Q4 2022 | 2022-12-31 | 30.1M | 696,379 | +2.37% |
| Q3 2022 · Sep 30 | 2022-09-30 | 28.6M | 901,844 | +3.25% |
| Q3 2022 · Sep 20 | 2022-09-20 | 1.5M | −16.0M | −91.70% |
| Q2 2022 | 2022-06-30 | 30.0M | 12.6M | +71.88% |
| Q1 2022 | 2022-03-31 | 29.4M | 12.7M | +75.56% |
| Q4 2021 | 2021-12-31 | 27.7M | 11.4M | +69.84% |
| Q3 2021 | 2021-09-30 | 17.5M | 1.3M | +8.11% |
| Q2 2021 | 2021-06-30 | 17.5M | 1.6M | +10.20% |
| Q1 2021 | 2021-03-31 | 16.7M | 1.8M | +12.10% |
| Q4 2020 | 2020-12-31 | 16.3M | 1.9M | +12.98% |
| Q3 2020 | 2020-09-30 | 16.2M | 6.3M | +62.91% |
| Q2 2020 | 2020-06-30 | 15.9M | 6.1M | +62.67% |
| Q1 2020 · Mar 31 | 2020-03-31 | 14.9M | −16.0M | −51.77% |
| Q4 2019 · Dec 31 | 2019-12-31 | 14.5M | −15.3M | −51.43% |
| Q1 2020 · Sep 30 | 2019-09-30 | 9.9M | −2.6M | −20.82% |
| Q4 2019 · Jun 30 | 2019-06-30 | 9.7M | −2.8M | −22.35% |
| Q3 2019 | 2019-03-31 | 31.0M | 18.4M | +146.88% |
| Q2 2019 | 2018-12-31 | 29.8M | 17.2M | +137.26% |
| Q1 2019 | 2018-09-30 | 12.5M | 4,750 | +0.04% |
| Q4 2018 | 2018-06-30 | 12.5M | 21,496 | +0.17% |
| Q3 2018 | 2018-03-31 | 12.5M | 508,958 | +4.23% |
| Q2 2018 | 2017-12-31 | 12.5M | 509,208 | +4.23% |
| Q1 2018 | 2017-09-30 | 12.5M | 509,208 | +4.23% |
| Q4 2017 | 2017-06-30 | 12.5M | 493,337 | +4.10% |
| Q3 2017 | 2017-03-31 | 12.0M | 20,750 | +0.17% |
| Q2 2017 | 2016-12-31 | 12.0M | 36,790 | +0.31% |
| Q1 2017 | 2016-09-30 | 12.0M | 1.0M | +9.28% |
| Q4 2016 | 2016-06-30 | 12.0M | 1.3M | +11.66% |
| Q3 2016 | 2016-03-31 | 12.0M | −41.7M | −77.63% |
| Q2 2016 | 2015-12-31 | 12.0M | −41.7M | −77.65% |
| Q1 2016 | 2015-09-30 | 11.0M | −32.8M | −74.88% |
| Q4 2015 | 2015-06-30 | 10.8M | −29.5M | −73.25% |
| Q3 2015 | 2015-03-31 | 53.7M | — | — |
| Q2 2015 | 2014-12-31 | 53.7M | — | — |
| Q1 2015 | 2014-09-30 | 43.9M | — | — |
| Q4 2014 | 2014-06-30 | 40.3M | — | — |
Relmada Therapeutics shares outstanding trends
Over the last five reported fiscal years, Relmada Therapeutics's shares outstanding moved from 16.3M to 73.3M, a change of 57.0M. The latest reported quarter, Q2 2026, shows 106.7M.
About the metric
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
Calculation and source
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when SEC-reported stock-split conversion ratios are available. Values remain as reported when no split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Relmada Therapeutics filings at SEC.gov ↗